Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Valuation of Corporate Innovation and the Pricing of Risk in the Biopharmaceutical Industry: The Case of Gilead

Valuation of Corporate Innovation and the Pricing of Risk in the Biopharmaceutical Industry: The... Much of a firm's market value derives from expected future growth value rather than from the value of current operations or assets in place. Pharmaceutical companies are good examples of firms where much market value comes from expectations about drugs still in the development “pipeline.” http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Applied Corporate Finance Wiley

Valuation of Corporate Innovation and the Pricing of Risk in the Biopharmaceutical Industry: The Case of Gilead

Download PDF
19 pages

Loading next page...
 
/lp/wiley/valuation-of-corporate-innovation-and-the-pricing-of-risk-in-the-IAEIiol3jn

References (13)

Publisher
Wiley
Copyright
Copyright © 2018 Cantillon and Mann
ISSN
1078-1196
eISSN
1745-6622
DOI
10.1111/jacf.12303
Publisher site
See Article on Publisher Site

Abstract

Much of a firm's market value derives from expected future growth value rather than from the value of current operations or assets in place. Pharmaceutical companies are good examples of firms where much market value comes from expectations about drugs still in the development “pipeline.”

Journal

Journal of Applied Corporate Finance – Wiley

Published: Jan 1, 2018

There are no references for this article.